Bispecific antibody that simultaneously binds BCMA on myeloma cells and CD3 on T cells, physically bringing T cells into contact with tumor cells to trigger TCR signaling, immune synapse formation, T‑cell activation and degranulation, resulting in MHC‑independent lysis of BCMA‑expressing myeloma cells.